查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417528

气喘和慢性阻塞性肺病治疗药物市场报告：2030 年趋势、预测和竞争分析

Asthma and COPD Drugs Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

气喘和慢性阻塞性肺病治疗药物的趋势和预测

至2030年，全球气喘和慢性阻塞性肺病药物市场预计将达到408亿美元，2024年至2030年的复合年增长率为4.3%。该市场的主要驱动力是呼吸系统疾病治疗方法的改进和新产品的推出、对标靶药物和生技药品的兴趣增加以及都市化和人口老化的加剧。由于气喘和慢性阻塞性肺病市场的机会，全球气喘和慢性阻塞性肺病药物市场的未来前景看好。

气喘与慢性阻塞性肺病药物市场洞察

Lucintel 预测，在预测期内，组合药物仍将是最大的细分市场。

由于气喘发病率不断增加、製造业中重要参与者的存在、吸烟习惯以及该地区已建立的基础设施，北美在预测期内仍将是最大的地区。

常问问题

Q1.市场规模有多大？

A1. 到 2030 年，全球气喘和慢性阻塞性肺病药物市场预计将达到 408 亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，全球气喘和慢性阻塞性肺病药物市场预计将以4.3%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动力是呼吸系统疾病治疗方法的改进和新产品的推出、对标靶药物和生技药品的兴趣增加以及都市化和人口老龄化的加剧。

Q4.市场的主要细分市场是什么？

A4.全球气喘和慢性阻塞性肺病药物市场前景广阔，气喘和慢性阻塞性肺病市场充满机会。

Q5.市场上主要企业有哪些？

A5. 主要的气喘和慢性阻塞性肺病治疗药物公司如下。

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计组合药物在预测期内仍将是其最大的细分市场。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于气喘发病率的增加、製造业重要参与者的存在、吸烟习惯以及该地区已建立的基础设施，在预测期内，北美将继续成为最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球气喘与慢性阻塞性肺病药物市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球气喘和慢性阻塞性肺病治疗药物市场趋势（2018-2023）和预测（2024-2030）
  • 按疾病分類的全球气喘和慢性阻塞性肺病药物市场
    • 气喘
    • COPD
  • 按药物类别分類的全球气喘和慢性阻塞性肺病治疗市场
    • 组合药物
    • 短效β2激动剂
    • 长效β2激动剂
    • 白三烯拮抗
    • 抗胆碱能药物
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球气喘和慢性阻塞性肺病药物市场（按地区）
  • 北美气喘与慢性阻塞性肺病药物市场
  • 欧洲气喘与慢性阻塞性肺病药物市场
  • 亚太气喘及慢性阻塞性肺病药物市场
  • 其他地区气喘及慢性阻塞性肺病药物市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球气喘和慢性阻塞性肺病药物市场按疾病分類的成长机会
    • 按药物类别分類的全球气喘和慢性阻塞性肺病药物市场成长机会
    • 全球气喘和慢性阻塞性肺病药物市场成长机会（按地区）
  • 全球气喘和慢性阻塞性肺病药物市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球气喘和慢性阻塞性肺病药物市场的产能扩张
    • 全球气喘和慢性阻塞性肺病治疗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries
简介目录

Asthma and COPD Drugs Trends and Forecast

The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets. The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030 with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

A more than 150-page report is developed to help in your business decisions.

Asthma and COPD Drugs by Segment

The study includes a forecast for the global asthma and COPD drugs by diseases, medication class, and region.

Asthma and COPD Drugs Market by Diseases [Shipment Analysis by Value from 2018 to 2030]:

  • Asthma
  • COPD

Asthma and COPD Drugs Market by Medication Class [Shipment Analysis by Value from 2018 to 2030]:

  • Combination Drugs
  • Short Acting Beta Agonists
  • Long Acting Beta Agonists
  • Leukotriene Antagonists
  • Anticholinergics
  • Others

Asthma and COPD Drugs Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Asthma and COPD Drugs Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies asthma and COPD drugs companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the asthma and COPD drugs companies profiled in this report include-

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries

Asthma and COPD Drugs Market Insights

Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Features of the Global Asthma and COPD Drugs Market

Market Size Estimates: Asthma and COPD drugs market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Asthma and COPD drugs market size by diseases, medication class, and region in terms of value ($B).

Regional Analysis: Asthma and COPD drugs market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, medication class, and regions for the asthma and COPD drugs market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the asthma and COPD drugs market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the asthma and COPD drugs market size?

Answer: The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030.

Q2. What is the growth forecast for asthma and COPD drugs market?

Answer: The global asthma and COPD drugs market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the asthma and COPD drugs market?

Answer: The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

Q4. What are the major segments for asthma and COPD drugs market?

Answer: The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets.

Q5. Who are the key asthma and COPD drugs market companies?

Answer: Some of the key asthma and COPD drugs companies are as follows.

  • Novartis
  • Glaxosmithkline
  • Organon
  • Boehringer Ingelheim International
  • Abbott Laboratories
  • AstraZeneca
  • Sanofi
  • Hoffmann-La Roche
  • Vectura Group
  • Teva Pharmaceutical Industries

Q6. Which asthma and COPD drugs market segment will be the largest in future?

Answer: Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

Q7. In asthma and COPD drugs market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the asthma and COPD drugs market by diseases (asthma and COPD), medication class (combination drugs, short acting beta agonists, long acting beta agonists, leukotriene antagonists, anticholinergics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Asthma and COPD Drugs Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Asthma and COPD Drugs Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Asthma and COPD Drugs Market by Diseases
    • 3.3.1: Asthma
    • 3.3.2: COPD
  • 3.4: Global Asthma and COPD Drugs Market by Medication Class
    • 3.4.1: Combination Drugs
    • 3.4.2: Short Acting Beta Agonists
    • 3.4.3: Long Acting Beta Agonists
    • 3.4.4: Leukotriene Antagonists
    • 3.4.5: Anticholinergics
    • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Asthma and COPD Drugs Market by Region
  • 4.2: North American Asthma and COPD Drugs Market
    • 4.2.2: North American Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
  • 4.3: European Asthma and COPD Drugs Market
    • 4.3.1: European Asthma and COPD Drugs Market by Diseases: Asthma and COPD
    • 4.3.2: European Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
  • 4.4: APAC Asthma and COPD Drugs Market
    • 4.4.1: APAC Asthma and COPD Drugs Market by Diseases: Asthma and COPD
    • 4.4.2: APAC Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
  • 4.5: ROW Asthma and COPD Drugs Market
    • 4.5.1: ROW Asthma and COPD Drugs Market by Diseases: Asthma and COPD
    • 4.5.2: ROW Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Asthma and COPD Drugs Market by Diseases
    • 6.1.2: Growth Opportunities for the Global Asthma and COPD Drugs Market by Medication Class
    • 6.1.3: Growth Opportunities for the Global Asthma and COPD Drugs Market by Region
  • 6.2: Emerging Trends in the Global Asthma and COPD Drugs Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Asthma and COPD Drugs Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Asthma and COPD Drugs Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Glaxosmithkline
  • 7.3: Organon
  • 7.4: Boehringer Ingelheim International
  • 7.5: Abbott Laboratories
  • 7.6: AstraZeneca
  • 7.7: Sanofi
  • 7.8: Hoffmann-La Roche
  • 7.9: Vectura Group
  • 7.10: Teva Pharmaceutical Industries